Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Structure Therapeutics Inc. (NASDAQ: GPCR) has received a consensus rating of "Buy" from eight brokerages, with an average 12-month price target of $75.71.
• The stock was trading at $19.37, which is significantly lower than its 12-month high of $45.37, indicating potential growth opportunities.
• Recent quarterly earnings report showed a loss of ($0.36) EPS, missing analysts' consensus estimates of ($0.28), as analysts anticipate a -0.82 EPS for the current fiscal year.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $75.7143.

A number of research analysts have recently commented on GPCR shares. JMP Securities dropped their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. HC Wainwright reduced their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Citigroup began coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 target price for the company. Finally, Guggenheim decreased their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th.

Structure Therapeutics Stock Up 4.3%

GPCR opened at $19.37 on Friday. The company has a 50-day simple moving average of $19.28 and a 200 day simple moving average of $21.23. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $45.37. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -18.45 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Sell-side analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $28,000. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $34,000. National Bank of Canada FI raised its stake in shares of Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares during the period. Assetmark Inc. lifted its holdings in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after purchasing an additional 820 shares during the last quarter. Finally, Virtus ETF Advisers LLC lifted its stake in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.